394 related articles for article (PubMed ID: 12177686)
21. Galantamine for vascular cognitive impairment.
Birks J; Craig D
Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
[TBL] [Abstract][Full Text] [Related]
22. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
23. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Small G; Erkinjuntti T; Kurz A; Lilienfeld S
CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
[TBL] [Abstract][Full Text] [Related]
24. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
Coyle JT; Geerts H; Sorra K; Amatniek J
J Alzheimers Dis; 2007 Jul; 11(4):491-507. PubMed ID: 17656829
[TBL] [Abstract][Full Text] [Related]
25. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
Olazarán J; García G
Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M; Eap CB
Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
[TBL] [Abstract][Full Text] [Related]
27. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.
Galasko D; Kershaw PR; Schneider L; Zhu Y; Tariot PN
J Am Geriatr Soc; 2004 Jul; 52(7):1070-6. PubMed ID: 15209643
[TBL] [Abstract][Full Text] [Related]
28. Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
Tariot PN
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S26-33. PubMed ID: 11669506
[TBL] [Abstract][Full Text] [Related]
29. Update on Alzheimer drugs (galantamine).
Raskind MA
Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
[TBL] [Abstract][Full Text] [Related]
30. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
31. Galantamine: a review of its use in Alzheimer's disease and vascular dementia.
Corey-Bloom J
Int J Clin Pract; 2003 Apr; 57(3):219-23. PubMed ID: 12723727
[TBL] [Abstract][Full Text] [Related]
32. Nicotinic cholinergic modulation: galantamine as a prototype.
Woodruff-Pak DS; Lander C; Geerts H
CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
[TBL] [Abstract][Full Text] [Related]
33. Metrifonate for Alzheimer's disease.
López-Arrieta JM; Schneider L
Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
[TBL] [Abstract][Full Text] [Related]
34. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
[TBL] [Abstract][Full Text] [Related]
35. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
[TBL] [Abstract][Full Text] [Related]
36. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
37. Galantamine: use in Alzheimer's disease and related disorders.
Bullock R
Expert Rev Neurother; 2004 Mar; 4(2):153-63. PubMed ID: 15853556
[TBL] [Abstract][Full Text] [Related]
38. Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.
Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Saunder T; Young K; Smith CL; Welch J; Woodward M; Wesnes KA; Savage G; Rowe CC
Psychopharmacology (Berl); 2009 Jan; 202(1-3):79-91. PubMed ID: 18949462
[TBL] [Abstract][Full Text] [Related]
39. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
40. Galantamine introduced in Europe.
Am J Alzheimers Dis Other Demen; 2001; 16(1):8. PubMed ID: 11416951
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]